Takeda Pharmaceutical Limited's Revenue in the fiscal year 2025 $ 30,079.37 millions
Takeda Pharmaceutical Limited's Revenue in the fiscal year 2024 $ 29,535.84 millions
Takeda Pharmaceutical Limited's Revenue in the fiscal year 2023 $ 29,793.78 millions
Takeda Pharmaceutical Limited's Revenue in the fiscal year 2022 $ 31,787.95 millions
Takeda Pharmaceutical Limited's Revenue in the fiscal year 2021 $ 30,165.89 millions
TAK Revenue first quarter 2026 Y/Y Growth Comment
Takeda Pharmaceutical Company Limited in the first quarter 2026 achieved Revenue of $ 7,654.94 millions compare to recorded in same quarter a year ago.
Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 137 other companies have achieved higher Revenue growth. While Takeda Pharmaceutical Company Limited' s Revenue no change of 0% ranks overall at the positon no. 2454 in the first quarter 2026.
In the I. Quarter 2026 Takeda Pharmaceutical Company Limited disclosed fall in Revenue from the fourth quarter by -73.77% to $ 7,654.94 millions, from $ 29,183.90 millions achived in the previous reporting period.
Within Major Pharmaceutical Preparations industry 223 other companies have achieved higher Revenue quarter on quarter growth. While Takeda Pharmaceutical Limited's Revenue growth quarter on quarter, overall rank is 4122.
In the I. Quarter 2026 Takeda Pharmaceutical Company Limited disclosed fall in Revenue from the fourth quarter by -73.77% to $ 7,654.94 millions, from $ 29,183.90 millions achived in the previous reporting period.
Within Major Pharmaceutical Preparations industry 223 other companies have achieved higher Revenue quarter on quarter growth. While Takeda Pharmaceutical Limited's Revenue growth quarter on quarter, overall rank is 4122.
Takeda Pharmaceutical Limited's 12 Months Revenue Growth Year on Year
Although Takeda Pharmaceutical Limited's Annual Revenue growth year on year were below company's average 9.96% , Revenue announced in the Mar 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1.84% year on year, from -0.87% in Mar 31 2024.
In the Healthcare sector 379 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1685 to 2454.
Although Takeda Pharmaceutical Limited's Annual Revenue growth year on year were below company's average 9.96% , Revenue announced in the Mar 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 1.84% year on year, from -0.87% in Mar 31 2024.
In the Healthcare sector 379 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1685 to 2454.
About Takeda Pharmaceutical Limited Revenue Growth Rates (TAK), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
What’s included here
Company: Takeda Pharmaceutical Co Ltd
(CIK 1395064).
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
